<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180416039323N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-09-18</date_registration>
      <primary_sponsor>Artesh University of Medical Sciences</primary_sponsor>
      <public_title>Evaluating the efficacy of electroacupuncture in comparison with physiotherapy for reducing pain and disability in soldiers diagnosed with patellar chondromalacia</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the efficacy of electroacupuncture in comparison with physiotherapy for reducing pain and disability in soldiers diagnosed with patellar chondromalacia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71950</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: For random allocating of two groups with the same size of 20 participants (40 patients in total), we used block randomization with different block sizes. The sizes of blocks would be a multiple of 2 and a divisor of 40. At first, the block sizes were selected randomly. Then, for each block, different permutations for equal group size were determined. Finally, one of the permutations was selected randomly. Random numbers were generated in an independent statistical office using Random Allocation Software Ver 1.0.0.</study_design>
      <phase>0 (exploratory trials)</phase>
      <hc_freetext>Chondromalacia patellae.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the electroacupuncture group, the patients lie on the bed and the treatment is performed at acupuncture points ST34, ST36, ST38, SP9, SP10, and GB34 with 30 x 0.3 mm needles. The needles are kept sterile and with a penetration depth of 10 mm for 20 minutes. Also, an electroacupuncture device made in China is will be used to deliver the current, with a frequency of 5 to 20 Hz and the intensity that is tolerated by the patient without significant muscle twitching. Patients will be prohibited to use any special medicine and only take 325 mg of acetaminophen daily. In both groups, stretching exercises for the calf and hamstring muscles and strengthening the quadriceps muscles will be taught to the patients. Intervention 2: Control group: In the physiotherapy group, patients were treated with 10 sessions of routine physiotherapy with modalities such as infrared, ultrasound and electrical stimulation. Patients will be prohibited to use any special medicine and only take 325 mg of acetaminophen daily. In both groups, stretching exercises for the calf and hamstring muscles and strengthening the quadriceps muscles will be taught to the patients.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Rezasoltani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>501 Hospital, Etemadzade Ave, Fatemi Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411718546</zip>
        <telephone>+98 21 4382 3476</telephone>
        <email>z.rezasoltani@ajaums.ac.ir</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zahra Rezasoltani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>501 Hospital, Etemadzade Ave, Fatemi Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411718546</zip>
        <telephone>+98 21 4382 3476</telephone>
        <email>z.rezasoltani@ajaums.ac.ir</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The presence of chondromalacia patella on the basis of patient's history
The course of the disease more than 2 months
Failure to improve with conservative treatment for at least one month</inclusion_criteria>
      <agemin>17 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>History of lower limb surgery
History of serious knee trauma in last 6 months or mild trauma in last 2 months
The presence of any evidence of internal or external damage to the knee joint by examination or X-ray
History of corticosteroid usage
History of any systemic disease such as diabetes, rheumatoid arthritis
Scar at the acupuncture site
The presence of any deformity in the knee joint such as genovarum/genovalgum</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M22.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chondromalacia patellae</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the electroacupuncture group, the patients lie on the bed and the treatment is performed at acupuncture points ST34, ST36, ST38, SP9, SP10, and GB34 with 30 x 0.3 mm needles. The needles are kept sterile and with a penetration depth of 10 mm for 20 minutes. Also, an electroacupuncture device made in China is will be used to deliver the current, with a frequency of 5 to 20 Hz and the intensity that is tolerated by the patient without significant muscle twitching. Patients will be prohibited to use any special medicine and only take 325 mg of acetaminophen daily. In both groups, stretching exercises for the calf and hamstring muscles and strengthening the quadriceps muscles will be taught to the patients.</i_keyword>
      <i_keyword>Control group: In the physiotherapy group, patients were treated with 10 sessions of routine physiotherapy with modalities such as infrared, ultrasound and electrical stimulation. Patients will be prohibited to use any special medicine and only take 325 mg of acetaminophen daily. In both groups, stretching exercises for the calf and hamstring muscles and strengthening the quadriceps muscles will be taught to the patients.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: Before the intervention, 3 months after the intervention. Method of measurement: The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 (‘no pain’) and 10 (‘pain as bad as it could possibly be’).</prim_outcome>
      <prim_outcome>Disability. Timepoint: Before the intervention, 3 months after the intervention. Method of measurement: The Visual Analogue Scale (VAS) measures disability intensity. The VAS consists of a 10cm line, with two end points representing 0 (‘no disability ’) and 10 (‘disability as bad as it could possibly be’).</prim_outcome>
      <prim_outcome>Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire. Timepoint: Before the intervention, 3 months after the intervention. Method of measurement: This questionnaire is designed to measure knee pain, symptoms, motor function problems in daily activities, sports, recreation and quality of life in the knee joint. It has 42 patient-centered questions, which examines 5 concepts related to the patient. The subjects used a 5-point Likert scale. There are five options for each question, and the answers are scored from 0 to 4, and the total points obtained in each sub-group are calculated from 0 to 100 points. The number zero indicates the maximum problem and the number 100 indicates the absence of the problem.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Artesh University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-07-17</approval_date>
        <contact_name>Ethics Committees of AJA University of Medical Sciences</contact_name>
        <contact_address>Imam Reza hospital, Etemad zade street, Fatemi street, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
